Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review

Article Hematology

A gene expression-based model predicts outcome in chil-dren with intermediate-risk classical Hodgkin lymphoma

Rebecca L. Johnston et al.

Summary: This study investigates the tumor microenvironment biology of pediatric cHL using gene expression profiling and develops a predictive model for pediatric cHL prognosis. It provides a risk-stratification tool for personalized therapy.

BLOOD (2022)

添加到收藏夹

Article Oncology

Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience

Fulvio Massaro et al.

Summary: Post-ASCT BV maintenance is an effective and safe treatment option for cHL patients, improving PFS. High-risk factors include refractory disease and high Deauville score post-ASCT, which are associated with reduced PFS.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study

Jianqiu Wu et al.

Summary: Camrelizumab demonstrates potent antitumor activity, good tolerability, and manageable safety in patients with relapsed or refractory classical Hodgkin lymphoma. Extended follow-up shows durable response, long survival, and rare occurrence of new side effects, with reactive capillary endothelial proliferation being the main observed adverse event.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma

Raphael Lievin et al.

Summary: HIV-infected patients with Hodgkin's lymphoma have altered distribution of B-lymphocytic subsets and increased production of activating cytokines. These factors may contribute to the process of tumorigenesis. The study found higher levels of activating cytokines in HIV-cHL patients compared to controls. The distribution of B-cell subsets was also different, with a higher proportion of naive B-cells. The results suggest that HIV-infected patients with cHL have a unique B-cell-related environment that may fuel tumorigenesis.

CANCERS (2022)

添加到收藏夹

Article Oncology

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

Fulvio Massaro et al.

Summary: This retrospective study evaluated the efficacy of a combination of brentuximab vedotin and pembrolizumab as a bridge treatment to autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin lymphoma (HL) patients. The results showed that this combination therapy is highly effective for high-risk patients.

CANCERS (2022)

添加到收藏夹

Review Oncology

Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

Vivek S. Radhakrishnan et al.

Summary: The study reviewed 179 cases of patients with R/R classical Hodgkin lymphoma who received BBv salvage therapy and found that BBv had good activity and tolerability in refractory and advanced disease. Survival rate analysis showed that patients with a good response to BBv had a higher survival probability.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

Timothy J. Voorhees et al.

Summary: This study found an association between high baseline MTV and inferior PFS in patients with r/r cHL treated with CD30.CAR-T cell therapy.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani et al.

Summary: The study demonstrated significant improvements in health-related quality of life measures with pembrolizumab compared to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Matthew G. Mei et al.

Summary: This phase 2 trial evaluated the efficacy of PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide as salvage therapy in patients with relapsed/refractory classical Hodgkin lymphoma. The results showed that this treatment approach was well tolerated and effective, leading to a high complete response rate and successful bridging to autologous hematopoietic cell transplantation in most patients.

BLOOD (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study

Ningjing Lin et al.

Summary: GLS-010 (zimberelimab) demonstrates effectiveness and safety in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. The objective response rate assessed by an independent radiology review committee was 90.6%, with a complete response rate of 32.9%. The 12-month progression-free survival and overall survival rates were 78% and 99%, respectively.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Hematology

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

Ajay Major et al.

Summary: The PI3K/Akt/mTOR axis is activated in multiple lymphoma subtypes and is a potential therapeutic target. This study evaluated the combination therapy of the mTOR inhibitor temsirolimus and the immunomodulatory agent lenalidomide in relapsed and refractory lymphoma patients. The results showed promising activity, especially in relapsed/refractory classical Hodgkin lymphoma patients.

HAEMATOLOGICA (2022)

添加到收藏夹

Letter Hematology

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability

Naike Casagrande et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Oncology

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience

Marina Moretti et al.

Summary: The combination of brentuximab vedotin and bendamustine (BVB) shows good efficacy and tolerability in patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL), regardless of stem cell transplantation (SCT) eligibility. BVB can be used as a bridge to SCT or as a definitive therapy for SCT-ineligible patients.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group

Rahul R. Parikh et al.

Summary: In the treatment of high-risk cHL patients, most relapses occur in non-bulky initial sites, mainly due to response-adapted radiation therapy given to patients with bulky disease. This study found low rates of failures outside of the personalized radiation treatment volumes, and FDG uptake on PET2 did not accurately identify most relapse sites.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Hematology

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Marie Jose Kersten et al.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen et al.

Summary: Brief pembrolizumab monotherapy followed by AVD is highly effective and safe for patients with newly diagnosed classical Hodgkin lymphoma, including those with bulky disease.

BLOOD (2021)

添加到收藏夹

Letter Hematology

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series

Annabel McMillan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Josefa Dela Cruz Chuh et al.

Summary: Early success with brentuximab vedotin in treating classical Hodgkin lymphoma led to the development of multiple MMAE antibody-drug conjugates, but most of these have not been successful in clinical trials. This study describes the development of second-generation therapeutic ADCs targeting Ly6E, with a focus on using DNA-damaging agents to improve durability of response. The new ADCs showed promising preclinical efficacy in driving tumor regression and reducing the likelihood of resistance compared to traditional MMAE-based conjugates.

MABS (2021)

添加到收藏夹

Article Oncology

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Francois Laliberte et al.

Summary: This observational study compared healthcare resource utilization (HRU) between patients with classical Hodgkin lymphoma (cHL) initiated on pembrolizumab and nivolumab in the USA. Patients initiated on pembrolizumab had significantly lower rates of all-cause and cHL-related hospitalizations compared to patients initiated on nivolumab.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Review Oncology

A New Target for Hodgkin Lymphoma-Camidanlumab Tesirine

Narendranath Epperla et al.

Summary: Camidanlumab Tesirine (Cami) has shown activity in multiply relapsed/refractory classical Hodgkin lymphoma (cHL) patients. Treatment with Cami was associated with adverse events, but overall clinical efficacy is encouraging.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

添加到收藏夹

Article Oncology

Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma

Naike Casagrande et al.

Summary: Trabectedin, a novel drug candidate, demonstrates potent antitumor activity against Hodgkin Reed Sternberg cells by targeting tumor cells and the tumor microenvironment. It induces necroptosis, DNA damage, cell cycle arrest, and reduces secretion of inflammatory mediators, as well as inhibits migration. In preclinical studies, trabectedin shows promising results in inhibiting tumor growth and reducing tumor-associated macrophages and angiogenesis in Hodgkin lymphoma xenografts.

CANCER LETTERS (2021)

添加到收藏夹

Article Hematology

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Ranjana H. Advani et al.

Summary: This study evaluated the combination of BV and Nivo as first salvage therapy for r/r cHL patients, showing high objective response rate and progression-free survival without additional toxicity concerns. Some patients were able to directly proceed to transplant after study treatment, indicating durable efficacy and impressive outcomes.

BLOOD (2021)

添加到收藏夹

Article Hematology

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

Alex F. Herrera et al.

Summary: In this study, the addition of 90Y-antiCD25 (aTac) to BEAM AHCT for high-risk relapsed or refractory classical Hodgkin lymphoma (HL) patients was shown to be safe and effective, with favorable outcomes observed in terms of toxicity, engraftment, and overall survival. Further evaluation of this approach in a phase 2 trial is ongoing to assess its efficacy.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Oncology

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Yang Liu et al.

Summary: The combination of camrelizumab and decitabine leads to longer progression-free survival in patients with relapsed/refractory cHL compared to camrelizumab monotherapy, showing superior efficacy and potential as a biomarker for treatment response in certain patient subgroups.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

Yuqin Song et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Victor M. Orellana-Noia et al.

Summary: The study highlights the importance of ADL loss in predicting disease progression and overall survival in older patients with classic Hodgkin lymphoma. Conventional chemotherapy regimens significantly improved progression-free and overall survival, with similar outcomes observed in patients aged 60-69 and those aged 70 and over. Early treatment discontinuation due to toxicity was more common in patients with higher CIRS-G scores or documented geriatric syndromes, emphasizing the need for comprehensive geriatric assessments in determining fitness for therapy.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Chemistry, Multidisciplinary

Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy

Chen-yu Wang et al.

Summary: The population pharmacokinetic analysis of camrelizumab showed that patient characteristics do not have a clinically meaningful impact on its pharmacokinetics, and there is no advantage of either the flat dose or weight-based dose regimen for most patients with advanced solid tumors.

ACTA PHARMACOLOGICA SINICA (2021)

添加到收藏夹

Article Oncology